Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

European Commission Competition DG releases final report on pharmaceutical sector (IPKat) (PatLit) (BLOG@IP::JUR) (IAM) (Managing Intellectual Property) (Intellectual Property Watch) (The SPC Blog) (IAM)

US: Follow-on biologics proposals considered by US Senate HELP Committee; Committee passes amendment for 12-year biologics exclusivity period (FDA Law Blog) (Patent Baristas) (GenericsWeb) (FDA Law Blog) (Patent Docs) (Patent Docs) (Patent Docs) (Patent Docs) (Patent Docs)

Fuzeon (Enfuvirtide) – Korea: Request for compulsory license for Fuzeon denied (Korea IP Law Blog)

Patents and pandemics (Patent Baristas)

World Customs Organisation meeting 25-27 June: Counterfeiting and Piracy (CAP) committee replaces controversial SECURE group, new mandate on health (Intellectual Property Watch)

G8 public health report cites IP, innovation (Intellectual Property Watch) (Intellectual Property Watch)

How to avoid the coming drug access crisis – interview with Ellen’t Hoen, Senior IP Advisor at UNITAID (Intellectual Property Watch)

European Commission Competition DG releases final report on pharmaceutical sector (IPKat) (PatLit) (BLOG@IP::JUR) (IAM) (Managing Intellectual Property) (Intellectual Property Watch) (The SPC Blog) (IAM)

India: Impact of TRIPS on generic pharmaceuticals in India – A research endeavour in Delhi (IP Osgoode)

Kenya: AIDS/HIV patients accuse 2008 Anti-Counterfeiting Act of being unconstitutional on the grounds that it could rob them of their right to life (Afro-IP) (Michael Geist)

UK: EWHC on what first authorisation means: Generics (UK) v Synaptech Inc (The SPC Blog)

US: Follow-on biologics proposals considered by US Senate HELP Committee; Committee passes amendment for 12-year biologics exclusivity period (FDA Law Blog) (Patent Baristas) (GenericsWeb) (FDA Law Blog) (Patent Docs) (Patent Docs) (Patent Docs) (Patent Docs) (Patent Docs)

US: CAFC: ‘Enola’ Mexican yellow bean patent finally cooked: In re POD-NERS (Patently-O)

Actos (Pioglitazone) – US: Takeda files patent infringement lawsuits against Torrent Pharmaceuticals in Delaware and S D New York following Torrent’s ANDA to manufacture generic Actos (Patent Docs)

Amrix (Cyclobenzaprine) – US: Eurand, Cephalon and Anesta file patent infringement suit against Anchen over ANDA to manufacture generic Amrix (Patent Docs)

Cozaar/Hyzaar (Losartan) – US: Generic Cozaar/Hyzaar 180-day exclusivity litigation update – FDA files motion to dismiss; Apotex seeks to intervene; Teva replies (FDA Law Blog)

Effexor (Venlafaxine) – US: Wyeth files patent infringement lawsuit against Orgenus over ANDA to produce generic Effexor (Patent Docs)

Fuzeon (Enfuvirtide) – Korea: Request for compulsory license for Fuzeon denied (Korea IP Law Blog)

Glivec (Imatinib) – India: Too pricey for a patent? IPAB rejects Novartis’ patent application for Glivec (Intellectual Property Watch)

Lescol (Fluvastatin) – Netherlands: No interim relief pending appeal against invalidity, rules District Court of The Hague: Novartis v Mylan and Actavis (PatLit)

Levaquin (Levoflaxacin) – Canada: FCA holds generics raising allegations similar to those of previous generics allowed their day in court: Apotex v Janssen-Ortho (Global IP Watch)

Lexapro (Escitalopram) – US: Caraco Pharmaceuticals enters into asset purchase agreement with Forest Laboratories to settle Lexapro ANDA patent litigation (SmartBrief)

Lexapro (Escitalopram) – US: Forest Laboratories and H Lundbeck enter into settlement agreement with Sun and Caraco related to Lexapro patent litigation (SmartBrief)

Luxiq (Betamethasone) – US: Motion to amend pleadings granted –relevant delay is to trial date: Connetics Corp v Pentech Pharms (Chicago Intellectual Property Law Blog)

Opana (Oxymorphone) – US: Endo files patent infringement suit against Barr in response to Para IV certification as part of ANDA to manufacture generic ANDA (Patent Docs)

Oracea (Doxycycline) – US: Research Foundation of State University of New York, New York University and Galderma file patent infringement suit against Lupin following its ANDA to manufacture generic Oracea (Patent Docs) (GenericsWeb)

Renagel (Sevelamer) – US: Genzyme files patent infringement suit against Sandoz over its ANDA to manufacture generic Renagel (Patent Docs)

Saridon (Propyphenazone, Paracetamol, Caffeine) – China: Supreme People’s Court affirms Southwest Pharma’s trade mark right to Sanlietong, which bear same Chinese characters as Roche’s Saridon trade mark (S&F)

Valtrex (Valaciclovir) – US: Apotex files patent infringement suit against Glaxo Wellcome over ANDA to manufacture generic Valtrex (Patent Docs)